The U.S. pharmaceutical industry is bracing for a possible wave of tariffs on foreign-made drugs, even as they received a short-term exemption this week under President Donald Trump’s sweeping new ...
The pharmaceutical industry avoided immediate tariffs under President Donald Trump’s latest trade actions, though future levies remain a possibility. Here are four things to know: ...
Fear of the future of healthcare is raising concern for Black medical students with aspirations of helping those in need.
GlobalData on MSN2d
Advancement of serialisation and labelling at PHARMAP 2025With counterfeit drugs making up 30% of global sales, regulators are tightening serialisation and labelling rules to secure ...
In recent years, the pharmaceutical landscape has witnessed a seismic shift as cannabinoids transition from niche alternatives to mainstream medical solutions.
AfroTech on MSN8h
FAMU Loses $16.3M Grant That Reportedly Helped Produce 60% Of The Nation’s Ph.D. Graduates In Pharmaceutical SciencesFlorida A&M University (FAMU) has lost a significant grant that helped produced 60% of the nation’s Ph.D. graduates in ...
The talks between the administration and the industry, which have been taking place behind closed doors, have given some ...
Amid a raft of federal changes cutting funding and capacities at the Food and Drug Administration, investors are soon ...
The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...
The boss of US pharmaceutical giant Eli Lilly has told the BBC there is no looking back from Donald Trump's decision to ...
Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are ...
The drug industry won a reprieve from sweeping tariffs announced by President Donald Trump on Wednesday, though it could be ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback